• linkedin
  • Increase Font
  • Sharebar

    Is favorable-risk GG2 prostate Ca suitable for active surveillance?

    FR-GG2 patients more likely to demonstrate worse pathology, higher recurrence rate

    Badar M. Mian, MDBadar M. Mian, MD

    “Journal Article of the Month” is a new Urology Times section in which Badar M. Mian, MD (left), offers perspective on noteworthy research in the peer-reviewed literature.  Dr. Mian is associate professor of surgery in the division of urology at Albany Medical College, Albany, NY.

    Indications for active surveillance for early-stage prostate cancer have expanded recently to include select patients (PSA <10.0 ng/mL, cT2a) with Gleason score 3+4 or Grade Group 2 (GG2) prostate cancer as per National Comprehensive Cancer Network guidelines. In a study published online ahead of print in the Journal of Urology (Dec. 7, 2017), Gearman and colleagues sought to determine the suitability of active surveillance for favorable-risk GG2 (FR-GG2) cancer by analyzing the risk of adverse pathology and oncologic outcomes for surgically treated patients. The authors report that among the potential candidates for active surveillance, those with FR-GG2 were more likely to demonstrate worse pathology and higher rate of cancer recurrence than those with GG1. 

    Also by Dr. Mian: Robotic radical nephrectomy sees steady increase in use

    The authors performed a retrospective review of radical prostatectomy patients and identified 1,735 patients with FR-GG2 prostate cancer (PSA <10.0 ng/mL, T2a) and 6,360 men with GG1. The FR-GG2 group had a higher rate of palpable disease. Following prostatectomy, the FR-GG2 group, in comparison to GG1, had a higher rate of extraprostatic extension (11.6% vs. 4.2%), seminal vesicle invasion (4.6% vs. 1.7%), and lymph node involvement (1.8% vs. 0.3%). On multivariable analysis, patients with FR-GG2 were significantly more likely to have non-organ-confined disease, but increased risk of seminal vesicle invasion and lymph node involvement did not reach statistical significance.

    Men with FR-GG2 had worse estimated 10-year PSA recurrence-free survival (81.2% vs. 88.9%) and systemic progression-free survival (96.5% vs. 99%). Prostate cancer-specific and overall mortality were both slightly higher in the FR-GG2 group (0.9% vs. 0.4% and 10.1 vs. 8.2, respectively). As one might expect from the pathology and PSA recurrence, the FR-GG2 group received additional therapy (radiation and/or hormonal therapy) at a higher rate by about 5%-6%.

    Next: Lengthy study period introduces confounders


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available